Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 5/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | KDM5A | P29375 | 6/20 | 0.51 |
| ▸ | CHUK | O15111 | 4/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | IKBKB | O14920 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PIM1 | P11309 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9533317 | 0.84 | PARP1 (0.62) | PARP1KDM4ECA12CA9CHUK | |
| SCHEMBL9979350 | 0.81 | PARP1 (0.59) | PARP1KDM4EKDM5ACHUKGABRP | |
| SCHEMBL10134605 | 0.80 | PARP1 (0.79) | PARP1KDM4EKDM5ACHUKGABRP | |
| SCHEMBL29484414 | 0.80 | PARP1 (0.79) | PARP1KDM4EKDM5ACHUKGABRP | |
| SCHEMBL31625660 | 0.79 | PDE3B (0.52) | PARP1KDM4EKDM5ACHUKGABRP | |
| SCHEMBL259923 | 0.79 | PDE3B (0.52) | PARP1KDM4EKDM5ACHUKGABRP | |
| SCHEMBL12750475 | 0.77 | PARP1 (1.00) | PARP1KDM4EKDM5ACHUKGABRP | |
| SCHEMBL30322777 | 0.75 | CHUK (0.78) | PARP1KDM4EKDM5ACHUKGABRP | |
| SCHEMBL12396541 | 0.75 | CHUK (0.78) | PARP1KDM4EKDM5ACHUKGABRP | |
| SCHEMBL12432727 | 0.75 | PARP1 (0.52) | PARP1KDM4EKDM5ACHUKGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313535-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2025-10-09 | — | — | US | claimed |
| EP-4522589-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | Dice Molecules Sv, Inc. (US) | 2025-03-19 | — | — | EP | claimed |
| CN-119562944-A | Alpha 4 beta 7 integrin modulators and uses thereof | 戴斯分子SV有限公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2023220741-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | ANDRIANJARA CHARLES (FR) | 2005-01-06 | — | — | US | claimed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| US-20250313535-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | DICE MOLECULES SV, INC. | 2025-10-09 | — | — | US | disclosed |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-09-18 | — | — | US | disclosed |
| EP-4522589-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | Dice Molecules Sv, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20250084060-A1 | PRMT5 INHIBITORS AND METHODS OF TREATMENT | HANGZHOU UNOGEN BIOTECH, LTD. (CN) | 2025-03-13 | — | — | US | disclosed |
| CN-119562944-A | Alpha 4 beta 7 integrin modulators and uses thereof | 戴斯分子SV有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-114621222-B | 6-6 Fused bicyclic heteroaryl compounds and their use as LATS inhibitors | 诺华股份有限公司 | 2024-12-17 | — | — | CN | disclosed |
| EP-4444289-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-7192967-B1 | Cyclic imide-substituted pyridylalkane, alkene, alkine carboxamides useful as cytostatic and immunosuppressive agents | ASTELLAS PHARMA GMBH (DE) | 2007-03-20 | — | — | US | disclosed |
| US-20060199803-A1 | Compounds | KUDOS PHARMACEUTICALS LTD (GB) | 2006-09-07 | — | — | US | disclosed |
| WO-2006090169-A1 | 2,4-DIAMINO-PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE AS MTOR INHIBITORS | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-08-31 | — | — | WO | disclosed |
| WO-2005051316-A2 | POLYMER COMPOSITIONS AND METHODS FOR THEIR USE | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | disclosed |
| US-3947442-A | Method for producing heterocyclic acid anhydrides and pyrimidinediones | THE SHERWIN-WILLIAMS COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
| US-3947416-A | Azaisatoic anhydrides | THE SHERWIN-WILLIAMS COMPANY (US) | 1976-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004126-A1 | Method of determining potential allosterically-binding matrix metalloproteinase inhibitors | MMP13, MMP12, MMP25 | PARP1 3245/4885KDM4E 2484/4885CA12 1055/4885 |
| US-20060199803-A1 | Compounds | MTOR, RICTOR, RPTOR | PARP1 1795/4885KDM4E 1370/4885CA12 3932/4885 |
| US-20250313535-A1 | ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF | ITGB7, ITGB4, ITGA4 | PARP1 3381/4885KDM4E 1308/4885CA12 3762/4885 |
| US-20250288589-A1 | PYRIDOPYRIMIDINES AND METHODS OF THEIR USE | PNPO, DPYD, PYGB | PARP1 433/4885KDM4E 3908/4885CA12 4417/4885 |
| US-20250084060-A1 | PRMT5 INHIBITORS AND METHODS OF TREATMENT | PRMT5, PRMT3, PRMT1 | PARP1 260/4885KDM4E 54/4885CA12 4523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.